Cargando…

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement

Pituitary tumors, that origin from excessive proliferation of a specific subtype of pituitary cell, are mostly benign tumors, but may cause significant morbidity in affected patients, including visual and neurologic manifestations from mass-effect, or endocrine syndromes caused by hormone hypersecre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peverelli, Erika, Treppiedi, Donatella, Giardino, Elena, Vitali, Eleonora, Lania, Andrea G., Mantovani, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686608/ https://www.ncbi.nlm.nih.gov/pubmed/26733942 http://dx.doi.org/10.3389/fendo.2015.00187

Ejemplares similares

Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations
por: Peverelli, Erika, et al.
Publicado: (2022)

Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior
por: Mantovani, Giovanna, et al.
Publicado: (2019)

A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation
por: Mangili, Federica, et al.
Publicado: (2021)

SAT-312 Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on Akt Phosphorylation and Cell Proliferation in Pituitary Tumors
por: Mangili, Federica, et al.
Publicado: (2020)

MON-465 SST2 Trafficking Through The Cytoskeleton: Role Of Scaffolding Proteins Filamin A And β-arrestin 2
por: Treppiedi, Donatella, et al.
Publicado: (2019)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
por: Mangili, Federica, et al.
Publicado: (2022)

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST(2) and SST(5) homo- and hetero-dimer formation
por: Treppiedi, Donatella, et al.
Publicado: (2022)

TMPRSS2 Expression and Activity Modulation by Sex-Related Hormones in Lung Calu-3 Cells: Impact on Gender-Specific SARS-CoV-2 Infection
por: Treppiedi, Donatella, et al.
Publicado: (2022)

PMON171 DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Pituitary Neuroendocrine Tumoral Cells
por: Mangili, Federica, et al.
Publicado: (2022)

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
por: Di Muro, Genesio, et al.
Publicado: (2023)

Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer
por: Treppiedi, Donatella, et al.
Publicado: (2022)

SAT-566 Cofilin Is a Mediator of RET-Promoted Medullary Thyroid Carcinoma Cell Migration, Invasion and Proliferation
por: Peverelli, Erika, et al.
Publicado: (2019)

SUN-213 The Role of Filamin A (FLNA) in the Regulation of Insulin-Like Growth Factor System in Adrenocortical Carcinomas
por: Peverelli, Erika, et al.
Publicado: (2020)

Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant
por: Treppiedi, Donatella, et al.
Publicado: (2021)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

The role of somatostatin analogues in treatment of TSH secreting pituitary adenomas
por: Zgliczyński, Wojciech, et al.
Publicado: (2013)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Pivonello, Claudia, et al.
Publicado: (2022)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
por: Shamsi, Bilal Haider, et al.
Publicado: (2021)

Combination of transsphenoidal endoscopic surgery and presurgical somatostatin analogs in thyrotropin (TSH)-secreting pituitary adenomas: Treatment outcome and long-term remission at a single pituitary center
por: Liu, Jie, et al.
Publicado: (2022)

A Rare Case of Thyrotropin Secreting Pituitary Macroadenoma Primarily Treated With Somatostatin Analogue
por: Elsheikh, Arwa Mahmoud, et al.
Publicado: (2021)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

SAT-LB24 Association of Expression of Somatostatin Receptor 2 Subtype in Non-Pituitary Neuroendocrine Tumors With Response to Treatment With Somatostatin Analogues
por: Siddiqui, Abdullah, et al.
Publicado: (2020)

Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines
por: Dicitore, A., et al.
Publicado: (2021)

Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly
por: VALEA, ANA, et al.
Publicado: (2015)

Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion
por: Trivellin, Giampaolo, et al.
Publicado: (2023)

Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas
por: Hinojosa-Amaya, José Miguel, et al.
Publicado: (2020)

Case Report: New CDKN1B Mutation in Multiple Endocrine Neoplasia Type 4 and Brief Literature Review on Clinical Management
por: Lavezzi, Elisabetta, et al.
Publicado: (2022)

Outcome of Endoscopic Transsphenoidal Surgery in Combination with Somatostatin Analogues in Patients with Growth Hormone Producing Pituitary Adenoma
por: Zhou, Tao, et al.
Publicado: (2014)

TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice
por: Halem, Heather A, et al.
Publicado: (2020)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Somatostatin receptors in congenital hyperinsulinism: Biology to bedside
por: van Albada, Mirjam E., et al.
Publicado: (2022)

Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia
por: Haris, Basma, et al.
Publicado: (2020)

Neuromedins U and S involvement in the regulation of the hypothalamo–pituitary–adrenal axis
por: Malendowicz, Ludwik K., et al.
Publicado: (2012)

Pituitary Remodeling Throughout Life: Are Resident Stem Cells Involved?
por: Laporte, Emma, et al.
Publicado: (2021)

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs
por: Treppiedi, Donatella, et al.
Publicado: (2022)

Grass Carp Follisatin: Molecular Cloning, Functional Characterization, Dopamine D1 Regulation at Pituitary Level, and Implication in Growth Hormone Regulation
por: Fung, Roger S. K., et al.
Publicado: (2017)

Androgens Regulate T47D Cells Motility and Invasion through Actin Cytoskeleton Remodeling
por: Montt-Guevara, Maria Magdalena, et al.
Publicado: (2016)

Somatostatin-IRES-Cre Mice: Between Knockout and Wild-Type?
por: Viollet, Cécile, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uqp29r8bu44krsfrita4a4pbus